Closed · NCD-21-01 · CFDA 92.002 · Discretionary
Notice of Funding Opportunity: State’s use of Quality-Adjusted Life Year (QALY) - Based Cost-Effectiveness Reports to Inform Medicaid Coverage for Prescription Drugs
Federal grant opportunity posted by National Council on Disability, cataloged on Grants.gov.
- $65K-$65K
- Award range
- Closed
- Status
- July 20, 2021
- Close date
- 1
- Expected awards
The verdict
Notice of Funding Opportunity: State’s use of Quality-Adjusted Life Year (QALY) - Based Cost-Effectiveness Reports to Inform Medicaid Coverage for Prescription Drugs is a closed discretionary listing from National Council on Disability that offered $65,000 -- $65,000 across 1 expected award. Future funding cycles may be published under the same CFDA number.
- $65K-$65K
- award range
- Closed
- application status
- 1
- expected award
- 92.002
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Notice of Funding Opportunity: State’s use of Quality-Adjusted Life Year (QALY) - Based Cost-Effectiveness Reports to Inform Medicaid Coverage for Prescription Drugs - is cataloged under number NCD-21-01 and tied to CFDA assistance listing 92.002, posted by National Council on Disability. Grants.gov currently shows the opportunity as closed, first posted on June 15, 2021 and last updated on June 14, 2021. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is $65,000 -- $65,000. It expects to issue 1 award. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on July 20, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
$65,000 -- $65,000
Close Date
July 20, 2021
Posted
June 15, 2021
Expected Awards
1
Instrument
Cooperative Agreement
Description
The National Council on Disability (NCD) seeks proposals for a report that examines the extent of state’s use of QALY-based cost-effectiveness studies issued by the Institute for Clinical and Economic Review (ICER) or international drug prices set in reliance on QALY based cost-effectiveness research, to inform which prescription drugs and treatments will be covered by their Medicaid programs. The findings in the report serve to assist federal and state policymakers and Congress, with the insight needed to make policy decisions designed to ensure the continued availability of necessary prescription drugs to people with chronic illnesses and disabilities. The report will also provide patient rights organizations, medical associations and educators, and persons with disabilities, with an understanding of health care policies, legislation, and initiatives that impact their lives.The report will identify the states that are using ICER QALY-based cost studies or international drug prices to inform Medicaid coverage decisions; will describe how the studies are being used, e.g., as a benchmark or cost-threshold; and will identify if and how reliance on these reports has impacted coverage of drugs and treatments for beneficiaries. It will also describe methodological alternatives to QALYs that consider patient values and preferences. The report will include findings and make recommendations aimed at the U.S. Department of Health and Human Services, state governments, and Congress to address any identified issues and any barriers to accessing prescription drugs caused by reliance on these studies and/or international drug prices.The full Notice of Funding Opportunity is posted at www.ncd.gov under the "Funding Opportunities" tab and on the NCD Home Page.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
Ana I Torres-Davis Attorney Advisor Phone 2022722019
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |